DXCM

SEC source: 0001093557-21-000177 · edgardoc.xml · nonDerivative · entry 3

Balo Andrew K · CIK 0001323190 · *

10b5-1 filing: Not disclosed

Ownership: Indirect · by Trust

Disclosed balance after: 13,695

F1 · shares: On March 5, 2021, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F5 · price: This transaction was executed in multiple trades at prices ranging from $430.270 to $430.919. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issurer full information regarding the number of shares and prices at which the transactions were effected.

F3 · ownership.nature: Shares are held by the Balo Family Trust U/A/D 4/6/2006, with respect to which the reporting person is a trustee.

SEC source: 0001093557-21-000177 · edgardoc.xml · nonDerivative · entry 2

Balo Andrew K · CIK 0001323190 · *

10b5-1 filing: Not disclosed

Ownership: Indirect · by Trust

Disclosed balance after: 15,405

F1 · shares: On March 5, 2021, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F4 · price: This transaction was executed in multiple trades at prices ranging from $429.141 to $429.401. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issurer full information regarding the number of shares and prices at which the transactions were effected.

F3 · ownership.nature: Shares are held by the Balo Family Trust U/A/D 4/6/2006, with respect to which the reporting person is a trustee.

SEC source: 0001093557-21-000177 · edgardoc.xml · nonDerivative · entry 1

Balo Andrew K · CIK 0001323190 · *

10b5-1 filing: Not disclosed

Ownership: Indirect · by Trust

Disclosed balance after: 15,805

F1 · shares: On March 5, 2021, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F2 · price: This transaction was executed in multiple trades at prices ranging from $428.125 to $429.060. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

F3 · ownership.nature: Shares are held by the Balo Family Trust U/A/D 4/6/2006, with respect to which the reporting person is a trustee.

SEC source: 0001093557-21-000175 · edgardoc.xml · nonDerivative · entry 1

Murphy Patrick Michael · CIK 0001692785 · EVP, Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,241

F1 · shares: On August 28, 2020, Mr. Murphy adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Murphy. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F2 · balance_after: Included in this number are 15,413 unvested restricted stock units, 5,634 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 5,874 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 3,905 of which were granted on March 8, 2019 and shall vest through March 8, 2022.

SEC source: 0001093557-21-000173 · edgardoc.xml · nonDerivative · entry 3

Pacelli Steven Robert · CIK 0001359098 · Managing Dir., Dexcom Ventures

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 51,242

F1 · shares: On June 15, 2020, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F5 · price: This transaction was executed in multiple trades at prices ranging from $427.36 to $427.91. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

F3 · balance_after: Included in this number are 16,171 unvested restricted stock units, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 5,874 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 4,996 of which were granted on March 8, 2019 and shall vest through March 8, 2022.

SEC source: 0001093557-21-000173 · edgardoc.xml · nonDerivative · entry 2

Pacelli Steven Robert · CIK 0001359098 · Managing Dir., Dexcom Ventures

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 51,701

F1 · shares: On June 15, 2020, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F4 · price: This transaction was executed in multiple trades at prices ranging from $426.165 to $427.13. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

F3 · balance_after: Included in this number are 16,171 unvested restricted stock units, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 5,874 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 4,996 of which were granted on March 8, 2019 and shall vest through March 8, 2022.

SEC source: 0001093557-21-000173 · edgardoc.xml · nonDerivative · entry 1

Pacelli Steven Robert · CIK 0001359098 · Managing Dir., Dexcom Ventures

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,241

F1 · shares: On June 15, 2020, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F2 · price: This transaction was executed in multiple trades at prices ranging from $424.50 to $425.17. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

F3 · balance_after: Included in this number are 16,171 unvested restricted stock units, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 5,874 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 4,996 of which were granted on March 8, 2019 and shall vest through March 8, 2022.

SEC source: 0001093557-21-000172 · edgardoc.xml · nonDerivative · entry 3

SKYLER JAY S · CIK 0001236386 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · by Partnership

Disclosed balance after: 13,968

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 7, 2020, and amended effective February 17, 2021. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Skyler.

F5 · price: This transaction was executed in multiple trades at prices ranging from $427.000 to $427.455. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

F3 · ownership.nature: Shares are held by Skyler Bach Family Limited Partnership, LLP, with respect to which the reporting person is a managing partner of the partnership and maintains voting rights of these shares.

SEC source: 0001093557-21-000172 · edgardoc.xml · nonDerivative · entry 2

SKYLER JAY S · CIK 0001236386 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · by Partnership

Disclosed balance after: 19,370

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 7, 2020, and amended effective February 17, 2021. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Skyler.

F4 · price: This transaction was executed in multiple trades at prices ranging from $426.00 to $426.99. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issurer full information regarding the number of shares and prices at which the transactions were effected.

F3 · ownership.nature: Shares are held by Skyler Bach Family Limited Partnership, LLP, with respect to which the reporting person is a managing partner of the partnership and maintains voting rights of these shares.

SEC source: 0001093557-21-000172 · edgardoc.xml · nonDerivative · entry 1

SKYLER JAY S · CIK 0001236386 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · by Partnership

Disclosed balance after: 27,704

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 7, 2020, and amended effective February 17, 2021. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Skyler.

F2 · price: This transaction was executed in multiple trades at prices ranging from $425.00 to $425.99. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

F3 · ownership.nature: Shares are held by Skyler Bach Family Limited Partnership, LLP, with respect to which the reporting person is a managing partner of the partnership and maintains voting rights of these shares.

SEC source: 0001093557-21-000169 · edgardoc.xml · nonDerivative · entry 1

Shrishrimal Sumi · CIK 0001850687 · SVP Chief Risk Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,986

F1 · shares: On November 25, 2020, Ms. Shrishrimal adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Ms. Shrishrimal. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F2 · balance_after: Included in this number are 7,553 unvested restricted stock units, 3,073 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 2,872 of which were granted on March 8, 2020 and shall vest through March 8, 2023 and 1,608 of which were granted on March 8, 2019 and shall vest through March 8, 2022.

SEC source: 0001093557-21-000167 · edgardoc.xml · nonDerivative · entry 1

Leach Jacob Steven · CIK 0001700255 · EVP Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 82,641

F1 · shares: On March 5, 2021, the reporting person adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Leach. The sale of shares set forth above were pursuant to the 10b5-1 Plan.

F2 · balance_after: Included in this number are 19,999 unvested restricted stock units, 7,171 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 7,832 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 4,996 of which were granted on March 8, 2019 and shall vest through March 8, 2022.

SEC source: 0001093557-21-000165 · edgardoc.xml · nonDerivative · entry 1

AUGUSTINOS NICHOLAS · CIK 0001238485 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,110

F1 · shares: On March 4, 2021, Mr. Augustinos adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Augustinos. The sale of shares set forth above were pursuant to the 10b5-1 Plan.

F2 · balance_after: Included in this number are 918 restricted stock units which were granted on May 21, 2021 and will vest on the earlier of the one year anniversary of the grant date or the date of DexCom Inc's 2022 Annual Meeting.

SEC source: 0001093557-21-000164 · edgardoc.xml · nonDerivative · entry 3

Balo Andrew K · CIK 0001323190 · *

10b5-1 filing: Not disclosed

Ownership: Indirect · by Trust

Disclosed balance after: 16,383

F4 · shares: On March 5, 2021, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F3 · balance_after: Shares are held by the Balo Family Trust U/A/D 4/6/2006, with respect to which the reporting person is a trustee.

SEC source: 0001093557-21-000164 · edgardoc.xml · nonDerivative · entry 2

Balo Andrew K · CIK 0001323190 · *

10b5-1 filing: Not disclosed

Ownership: Indirect · by Trust

Disclosed balance after: 18,774

F1 · shares: Shares were transferred from direct ownership to ownership under the Balo Family Trust U/A/D 4/6/2006, with respect to which the reporting person is a trustee.

F3 · balance_after: Shares are held by the Balo Family Trust U/A/D 4/6/2006, with respect to which the reporting person is a trustee.

SEC source: 0001093557-21-000164 · edgardoc.xml · nonDerivative · entry 1

Balo Andrew K · CIK 0001323190 · *

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,533

F1 · shares: Shares were transferred from direct ownership to ownership under the Balo Family Trust U/A/D 4/6/2006, with respect to which the reporting person is a trustee.

F2 · balance_after: Included in this number are 16,171 unvested restricted stock units, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 5,874 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 4,996 of which were granted on March 8, 2019 and shall vest through March 8, 2022.

SEC source: 0001093557-21-000161 · edgardoc.xml · nonDerivative · entry 1

Blackford Quentin S. · CIK 0001612451 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,942

F1 · shares: On February 17, 2021 Mr. Blackford adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Blackford. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F2 · balance_after: Included in this number are 37,709 unvested restricted stock units, 7,491 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 8,484 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 6,144 of which were granted on March 8, 2019 and shall vest through March 8, 2022 and 15,590 of which were granted on September 7, 2017 and shall vest through September 7, 2021.

SEC source: 0001093557-21-000156 · edgardoc.xml · nonDerivative · entry 1

Murphy Patrick Michael · CIK 0001692785 · EVP, Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,741

F1 · shares: On August 28, 2020, Mr. Murphy adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Murphy. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F2 · balance_after: Included in this number are 15,413 unvested restricted stock units, 5,634 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 5,874 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 3,905 of which were granted on March 8, 2019 and shall vest through March 8, 2022.

SEC source: 0001093557-21-000157 · edgardoc.xml · nonDerivative · entry 1

Shrishrimal Sumi · CIK 0001850687 · SVP Chief Risk Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,386

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · balance_after: Included in this number are 7,553 unvested restricted stock units, 3,073 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 2,872 of which were granted on March 8, 2020 and shall vest through March 8, 2023 and 1,608 of which were granted on March 8, 2019 and shall vest through March 8, 2022.

SEC source: 0001093557-21-000152 · edgardoc.xml · nonDerivative · entry 7

Pacelli Steven Robert · CIK 0001359098 · Managing Dir., Dexcom Ventures

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,321

F1 · shares: On June 15, 2020, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F8 · price: This transaction was executed in multiple trades at prices ranging from $351.00 to $351.16. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issurer full information regarding the number of shares and prices at which the transactions were effected.

F2 · balance_after: Included in this number are 16,171 unvested restricted stock units, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 5,874 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 4,996 of which were granted on March 8, 2019 and shall vest through March 8, 2022.

SEC source: 0001093557-21-000152 · edgardoc.xml · nonDerivative · entry 6

Pacelli Steven Robert · CIK 0001359098 · Managing Dir., Dexcom Ventures

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,381

F1 · shares: On June 15, 2020, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F7 · price: This transaction was executed in multiple trades at prices ranging from $349.92 to $350.90. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issurer full information regarding the number of shares and prices at which the transactions were effected.

F2 · balance_after: Included in this number are 16,171 unvested restricted stock units, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 5,874 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 4,996 of which were granted on March 8, 2019 and shall vest through March 8, 2022.

SEC source: 0001093557-21-000152 · edgardoc.xml · nonDerivative · entry 5

Pacelli Steven Robert · CIK 0001359098 · Managing Dir., Dexcom Ventures

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,836

F1 · shares: On June 15, 2020, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F6 · price: This transaction was executed in multiple trades at prices ranging from $348.85 to $349.63. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issurer full information regarding the number of shares and prices at which the transactions were effected.

F2 · balance_after: Included in this number are 16,171 unvested restricted stock units, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 5,874 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 4,996 of which were granted on March 8, 2019 and shall vest through March 8, 2022.

SEC source: 0001093557-21-000152 · edgardoc.xml · nonDerivative · entry 4

Pacelli Steven Robert · CIK 0001359098 · Managing Dir., Dexcom Ventures

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,996

F1 · shares: On June 15, 2020, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F5 · price: This transaction was executed in multiple trades at prices ranging from $347.51 to $347.76. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

F2 · balance_after: Included in this number are 16,171 unvested restricted stock units, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 5,874 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 4,996 of which were granted on March 8, 2019 and shall vest through March 8, 2022.

SEC source: 0001093557-21-000152 · edgardoc.xml · nonDerivative · entry 3

Pacelli Steven Robert · CIK 0001359098 · Managing Dir., Dexcom Ventures

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 53,076

F1 · shares: On June 15, 2020, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F4 · price: This transaction was executed in multiple trades at prices ranging from $346.45 to $346.74. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

F2 · balance_after: Included in this number are 16,171 unvested restricted stock units, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 5,874 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 4,996 of which were granted on March 8, 2019 and shall vest through March 8, 2022.

SEC source: 0001093557-21-000152 · edgardoc.xml · nonDerivative · entry 2

Pacelli Steven Robert · CIK 0001359098 · Managing Dir., Dexcom Ventures

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 53,260

F1 · shares: On June 15, 2020, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F3 · price: This transaction was executed in multiple trades at prices ranging from $345.18 to $345.34. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

F2 · balance_after: Included in this number are 16,171 unvested restricted stock units, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 5,874 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 4,996 of which were granted on March 8, 2019 and shall vest through March 8, 2022.

SEC source: 0001093557-21-000152 · edgardoc.xml · nonDerivative · entry 1

Pacelli Steven Robert · CIK 0001359098 · Managing Dir., Dexcom Ventures

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 53,340

F1 · shares: On June 15, 2020, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F2 · balance_after: Included in this number are 16,171 unvested restricted stock units, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 5,874 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 4,996 of which were granted on March 8, 2019 and shall vest through March 8, 2022.

SEC source: 0001093557-21-000153 · edgardoc.xml · nonDerivative · entry 1

Sylvain Jereme M · CIK 0001681267 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,508

F1 · shares: On May 26, 2020, Mr. Sylvain adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sylvain. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F2 · balance_after: Included in this number are 11,837 unvested restricted stock units, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 3,654 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 1,608 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 1,274 of which were granted on November 8, 2018 and shall vest through November 8, 2021.

SEC source: 0001093557-21-000148 · edgardoc.xml · nonDerivative · entry 2

TOPOL ERIC · CIK 0001468345 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 919

F2 · shares: The RSU Award was granted on May 21, 2021 and 100% of the RSU will vest on the earlier of the one year anniversary of the grant date or the date of DexCom Inc's 2022 Annual Meeting. Each share is represented by a restricted stock unit (RSU) that represents a contingent right to receive one share of DexCom, Inc. Common Stock upon settlement.

F3 · balance_after: Represents 919 restricted stock units which were granted on May 21, 2021 and will vest on the earlier of the one year anniversary of the grant date or the date of DexCom Inc's 2022 Annual Meeting.

SEC source: 0001093557-21-000147 · edgardoc.xml · nonDerivative · entry 2

SKYLER JAY S · CIK 0001236386 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 900

F2 · shares: The RSU Award was granted on May 21, 2021 and 100% of the RSU will vest on the earlier of the one year anniversary of the grant date or the date of DexCom Inc's 2022 Annual Meeting. Each share is represented by a restricted stock unit (RSU) that represents a contingent right to receive one share of DexCom, Inc. Common Stock upon settlement.

F3 · balance_after: Represents 900 restricted stock units which were granted on May 21, 2021 and will vest on the earlier of the one year anniversary of the grant date or the date of DexCom Inc's 2022 Annual Meeting.

SEC source: 0001093557-21-000146 · edgardoc.xml · nonDerivative · entry 1

Malady Kyle · CIK 0001760581 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,182

F1 · shares: The RSU Award was granted on May 21, 2021 and 100% of the RSU will vest on the earlier of the one year anniversary of the grant date or the date of DexCom Inc's 2022 Annual Meeting. Each share is represented by a restricted stock unit (RSU) that represents a contingent right to receive one share of DexCom, Inc. Common Stock upon settlement.

F2 · balance_after: Included in this number are 2,182 unvested restricted stock units, 910 of which were granted on May 21, 2021 and shall vest on the earlier of the one year anniversary of the grant or the date of DexCom Inc's 2022 Annual Meeting and 1,272 of which were granted on October 11, 2020 and shall vest through October 11, 2023.

SEC source: 0001093557-21-000145 · edgardoc.xml · nonDerivative · entry 2

KAHN BARBARA · CIK 0001520391 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 918

F2 · shares: The RSU Award was granted on May 21, 2021 and 100% of the RSU will vest on the earlier of the one year anniversary of the grant date or the date of DexCom Inc's 2022 Annual Meeting. Each share is represented by a restricted stock unit (RSU) that represents a contingent right to receive one share of DexCom, Inc. Common Stock upon settlement.

F3 · balance_after: Represents 918 restricted stock units which were granted on May 21, 2021 and will vest on the earlier of the one year anniversary of the grant date or the date of DexCom Inc's 2022 Annual Meeting.

SEC source: 0001093557-21-000144 · edgardoc.xml · nonDerivative · entry 1

Heller Bridgette P · CIK 0001485616 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,367

F1 · shares: The RSU Award was granted on May 21, 2021 and 100% of the RSU will vest on the earlier of the one year anniversary of the grant date or the date of DexCom Inc's 2022 Annual Meeting. Each share is represented by a restricted stock unit (RSU) that represents a contingent right to receive one share of DexCom, Inc. Common Stock upon settlement.

F2 · balance_after: Included in this number are 2,943 unvested restricted stock units, 919 of which were granted on May 21, 2021 and shall vest on the earlier of the one year anniversary of the grant or the date of DexCom Inc's 2022 Annual Meeting and 2,024 of which were granted on September 13, 2019 and shall vest through September 13, 2022.

SEC source: 0001093557-21-000138 · edgardoc.xml · nonDerivative · entry 2

FOLETTA MARK G · CIK 0001236389 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,054

F2 · shares: The RSU Award was granted on May 21, 2021 and 100% of the RSU will vest on the earlier of the one year anniversary of the grant date or the date of DexCom Inc's 2022 Annual Meeting. Each share is represented by a restricted stock unit (RSU) that represents a contingent right to receive one share of DexCom, Inc. Common Stock upon settlement.

F3 · balance_after: Represents 1,054 restricted stock units which were granted on May 21, 2021 and will vest on the earlier of the one year anniversary of the grant date or the date of DexCom Inc's 2022 Annual Meeting.

SEC source: 0001093557-21-000137 · edgardoc.xml · nonDerivative · entry 1

Dahut Karen M · CIK 0001533450 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,078

F1 · shares: The RSU Award was granted on May 21, 2021 and 100% of the RSU will vest on the earlier of the one year anniversary of the grant date or the date of DexCom Inc's 2022 Annual Meeting. Each share is represented by a restricted stock unit (RSU) that represents a contingent right to receive one share of DexCom, Inc. Common Stock upon settlement.

F2 · balance_after: Included in this number are 2,078 unvested restricted stock units, 918 of which were granted on May 21, 2021 and shall vest on the earlier of the one year anniversary of the grant or the date of DexCom Inc's 2022 Annual Meeting and 1,160 of which were granted on August 11, 2020 and shall vest through August 11, 2023.

SEC source: 0001093557-21-000136 · edgardoc.xml · nonDerivative · entry 2

Collins Richard Alexander · CIK 0001700619 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 910

F2 · shares: The RSU Award was granted on May 21, 2021 and 100% of the RSU will vest on the earlier of the one year anniversary of the grant date or the date of DexCom Inc's 2022 Annual Meeting. Each share is represented by a restricted stock unit (RSU) that represents a contingent right to receive one share of DexCom, Inc. Common Stock upon settlement.

F3 · balance_after: Represents 910 restricted stock units which were granted on May 21, 2021 and will vest on the earlier of the one year anniversary of the grant date or the date of DexCom Inc's 2022 Annual Meeting.

SEC source: 0001093557-21-000135 · edgardoc.xml · nonDerivative · entry 2

AUGUSTINOS NICHOLAS · CIK 0001238485 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,916

F3 · shares: The RSU Award was granted on May 21, 2021 and 100% of the RSU will vest on the earlier of the one year anniversary of the grant date or the date of DexCom Inc's 2022 Annual Meeting. Each share is represented by a restricted stock unit (RSU) that represents a contingent right to receive one share of DexCom, Inc. Common Stock upon settlement.

F4 · balance_after: Included in this number are 918 restricted stock units which were granted on May 21, 2021 and will vest on the earlier of the one year anniversary of the grant date or the date of DexCom Inc's 2022 Annual Meeting.

SEC source: 0001093557-21-000134 · edgardoc.xml · nonDerivative · entry 2

ALTMAN STEVEN R · CIK 0001191307 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 910

F2 · shares: The RSU Award was granted on May 21, 2021 and 100% of the RSU will vest on the earlier of the one year anniversary of the grant date or the date of DexCom Inc's 2022 Annual Meeting. Each share is represented by a restricted stock unit (RSU) that represents a contingent right to receive one share of DexCom, Inc. Common Stock upon settlement.

F3 · balance_after: Represents 910 restricted stock units which were granted on May 21, 2021 and will vest on the earlier of the one year anniversary of the grant date or the date of DexCom Inc's 2022 Annual Meeting.

SEC source: 0001093557-21-000148 · edgardoc.xml · nonDerivative · entry 3

TOPOL ERIC · CIK 0001468345 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Family Holdings

Disclosed balance after: 91,847

F1 · shares: Shares were transferred from direct ownership to ownership under the Topol Family Holdings, LLC, upon vesting of previously awarded restricted stock units.

F4 · balance_after: Shares are held by Topol Family Holdings, LLC, with respect to which the reporting person is a manager and maintains voting rights of these shares.

F4 · ownership.nature: Shares are held by Topol Family Holdings, LLC, with respect to which the reporting person is a manager and maintains voting rights of these shares.

SEC source: 0001093557-21-000148 · edgardoc.xml · nonDerivative · entry 1

TOPOL ERIC · CIK 0001468345 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · shares: Shares were transferred from direct ownership to ownership under the Topol Family Holdings, LLC, upon vesting of previously awarded restricted stock units.

SEC source: 0001093557-21-000147 · edgardoc.xml · nonDerivative · entry 3

SKYLER JAY S · CIK 0001236386 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · by Partnership

Disclosed balance after: 33,968

F1 · shares: Shares were transferred from direct ownership to ownership under the Skyler Bach Family Limited Partnership, LLP, upon vesting of previously awarded restricted stock units.

F4 · ownership.nature: Shares are held by Skyler Bach Family Limited Partnership, LLP, with respect to which the reporting person is a managing partner of the partnership and maintains voting rights of these shares.

SEC source: 0001093557-21-000147 · edgardoc.xml · nonDerivative · entry 1

SKYLER JAY S · CIK 0001236386 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · shares: Shares were transferred from direct ownership to ownership under the Skyler Bach Family Limited Partnership, LLP, upon vesting of previously awarded restricted stock units.

SEC source: 0001093557-21-000145 · edgardoc.xml · nonDerivative · entry 3

KAHN BARBARA · CIK 0001520391 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · by Trust

Disclosed balance after: 7,666

F1 · shares: Shares were transferred from direct ownership to ownership under the Barbara Kahn TTEE Barbara Kahn Rev TRT DTD 6/26/96 & Robert Meyer TTEE Robert Meyer Rev Trst DTD 6/26/96, upon vesting of previously awarded restricted stock units.

F4 · balance_after: Shares are held by the Barbara Kahn TTEE Barbara Kahn Rev TRT DTD 6/26/96 & Robert Meyer TTEE Robert Meyer Rev Trst DTD 6/26/96, with respect to which the reporting person is a trustee.

F4 · ownership.nature: Shares are held by the Barbara Kahn TTEE Barbara Kahn Rev TRT DTD 6/26/96 & Robert Meyer TTEE Robert Meyer Rev Trst DTD 6/26/96, with respect to which the reporting person is a trustee.

SEC source: 0001093557-21-000145 · edgardoc.xml · nonDerivative · entry 1

KAHN BARBARA · CIK 0001520391 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · shares: Shares were transferred from direct ownership to ownership under the Barbara Kahn TTEE Barbara Kahn Rev TRT DTD 6/26/96 & Robert Meyer TTEE Robert Meyer Rev Trst DTD 6/26/96, upon vesting of previously awarded restricted stock units.

SEC source: 0001093557-21-000138 · edgardoc.xml · nonDerivative · entry 3

FOLETTA MARK G · CIK 0001236389 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · by Trust

Disclosed balance after: 14,097

F1 · shares: Shares were transferred from direct ownership to ownership under the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, upon vesting of previously awarded restricted stock units.

F4 · balance_after: Shares are held by the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, with respect to which the reporting person is a trustee.

F4 · ownership.nature: Shares are held by the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, with respect to which the reporting person is a trustee.

SEC source: 0001093557-21-000138 · edgardoc.xml · nonDerivative · entry 1

FOLETTA MARK G · CIK 0001236389 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · shares: Shares were transferred from direct ownership to ownership under the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, upon vesting of previously awarded restricted stock units.

SEC source: 0001093557-21-000136 · edgardoc.xml · nonDerivative · entry 3

Collins Richard Alexander · CIK 0001700619 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · by Trust

Disclosed balance after: 8,704

F1 · shares: Shares were transferred from direct ownership to ownership under the Richard A. Collins Revocable Trust upon vesting of previously awarded restricted stock units.

F4 · balance_after: Shares are held by the Richard A. Collins Revocable Trust, with respect to which the reporting person is a trustee.

F4 · ownership.nature: Shares are held by the Richard A. Collins Revocable Trust, with respect to which the reporting person is a trustee.

SEC source: 0001093557-21-000136 · edgardoc.xml · nonDerivative · entry 1

Collins Richard Alexander · CIK 0001700619 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · shares: Shares were transferred from direct ownership to ownership under the Richard A. Collins Revocable Trust upon vesting of previously awarded restricted stock units.

SEC source: 0001093557-21-000134 · edgardoc.xml · nonDerivative · entry 3

ALTMAN STEVEN R · CIK 0001191307 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · by Trust

Disclosed balance after: 13,786

F1 · shares: Shares were transferred from direct ownership to ownership under the Steven R. and Lisa J. Altman, TTEE's Altman Family Trust DTD 8/21/92, upon vesting of previously awarded restricted stock units.

F4 · balance_after: Shares are held by the Steven R. and Lisa J. Altman, TTEE's Altman Family Trust DTD 8/21/92, with respect to which the reporting person is a trustee.

F4 · ownership.nature: Shares are held by the Steven R. and Lisa J. Altman, TTEE's Altman Family Trust DTD 8/21/92, with respect to which the reporting person is a trustee.

SEC source: 0001093557-21-000134 · edgardoc.xml · nonDerivative · entry 1

ALTMAN STEVEN R · CIK 0001191307 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · shares: Shares were transferred from direct ownership to ownership under the Steven R. and Lisa J. Altman, TTEE's Altman Family Trust DTD 8/21/92, upon vesting of previously awarded restricted stock units.

SEC source: 0001093557-21-000128 · edgardoc.xml · nonDerivative · entry 7

SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 105,722

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 31, 2020, and amended effective December 16, 2020. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer.

F3 · balance_after: Included in this number are 42,356 unvested restricted stock units, 13,445 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,968 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 11,943 of which were granted on March 8, 2019 and shall vest through March 8, 2022.